Abbott and Genentech have formed a collaboration for the global research, development and commercialization of two of Abbott’s investigational anti-cancer compounds, ABT-263 and ABT-869. The companies will share further development and commercialization of the compounds. They will co-promote any resulting products in the U.S., while Abbott will promote any resulting products outside the U.S. Financial terms were not disclosed. These compounds represent promising scientific approaches ...